Huixin Lifetech completes ~￥100M Series A+ funding round from Legend Capital, leading the exosome field with cutting-edge technology

Recently, Huixin Lifetech announced the completion of a nearly 100 million Series A+ funding round. This round was led by Legend Capital. Over the past year, Huixin Lifetech has secured two consecutive rounds of near 100 million financing, fully demonstrating the capital market's high recognition of Huixin Lifetech's technological approach and industrial capabilities.

The newly raised funds will primarily be used to accelerate Huixin Lifetech's global business expansion. Huixin Lifetech will focus on exosomes, viruses, LNP, and other types of nanoparticles, aiming to build a highly integrated, fully automated separation and purification technology platform. This initiative will facilitate the transition from laboratory-scale processes to an industrial-level intelligent manufacturing system, continuously driving systematic improvements in cost, efficiency, and quality standards within the fields of biomanufacturing and precision medicine.

Huixin Lifetech is a life sciences enterprise driven by original underlying technologies. In 2021, Huixin Lifetech launched the fully automated exosome isolation and purification technology based on ultrasonic nanofiltration, which has been recognized by the international academic community as "a significant breakthrough in exosome industrialization." This achievement marks a critical pathway for advancing exosome separation technology from research to industrial application.

The technology system established based on this original breakthrough has formed a fully independent and controllable core technological moat for Huixin Lifetech. Huixin Lifetech has also gained continuous support from several professional investment institutions, including Legend Capital.

The core competitive advantage of Huixin Lifetech stems from its fully independent, original, and globally recognized technological framework. Huixin Lifetech's EXODUS fully automated exosome purification platform innovatively integrates negative pressure oscillation and dual-coupled harmonic mechanisms, pioneering the development of membrane vibration separation technology. This approach systematically overcomes the inherent limitations of traditional membrane separation, ultracentrifugation, and tangential flow processes, such as high hydraulic pressure, severe non-specific protein adsorption, restricted nanofiltration flux, and susceptibility to damage in bio-nanoparticles like exosomes and viruses. Consequently, it provides a highly efficient, standardized, and fully automated solution for nanoparticle separation and purification.

This platform offers systemic advantages in maintaining high biological activity, achieving high recovery rates, ensuring high purity, delivering exceptional batch-to-batch consistency, and enabling end-to-end automation. It significantly enhances separation and purification efficiency, helping downstream clients reduce production costs and increase capacity. As a result, it accelerates the progression of the exosome industry toward higher standards of scaled production and clinical translation.

With solid foundational technological expertise, Huixin Lifetech has established a comprehensive product portfolio spanning from research to industrial applications, a key factor in attracting sustained capital attention. To address diverse application scenarios, Huixin Lifetech has launched the research-grade EXODUS H-300/H-600 to meet small-scale laboratory sample processing needs, as well as the industrial-grade EXODUS T-2800, offering a GMP-compliant large-scale production solution. The system is paired with disposable exosome enrichment and purification kits, reliably supporting processes from laboratory-scale development to medium- and large-scale commercial manufacturing. The EXODUS T-2800 excels in processing large-volume samples, driving efficient scaling in exosome and cell-related fields and contributing to global biomedical and life sciences innovation.

Over the past year of market expansion, industrial clients now account for approximately 40% of Huixin Lifetech's revenue, with consumables sales growing rapidly, reflecting the sustained release of industrial demand. Huixin Lifetech's overall revenue continues to grow at a high pace, with downstream industries demonstrating accelerating positive momentum.

Figure 1: EXODUS, The World's First Automated Exosome Purification Instrument Platform

It is noteworthy that Huixin Lifetech's newly launched EXODUS M-600 Multi-Channel Nanoparticle Composite Purification System represents the first integration of multi-channel parallel processing, composite purification, and AI intelligent control. Compared to traditional single-channel solutions, this system achieves a several-fold increase in processing efficiency per cycle, fully demonstrating Huixin Lifetech's capabilities in technological iteration and engineering innovation. Moving forward, Huixin Lifetech will continue to introduce multi-channel and AI-enabled models, further expanding coverage across diverse application scenarios such as scientific research, process development, and industrial production, to meet the varied needs of global clients.

Figure 2: Huixin Lifetech's New Product EXODUS M-600: Multi-Channel Nanoparticle Composite Purification System

Over the past three years of commercialization, Huixin Lifetech's EXODUS platform has achieved cumulative installations of over 300 units and serves more than 500 global clients, with operations spanning the Americas, Asia, and Europe. The platform is widely adopted by top-tier universities, research institutions, and pharmaceutical companies worldwide, including the National Institute of Environmental Health Sciences (NIEHS) in the United States, Harvard Medical School, MD Anderson Cancer Center, Peking University, Tsinghua University, University College London, Peking Union Medical College Hospital, as well as globally listed exosome-focused companies such as Capricor Therapeutics. Additionally, the EXODUS platform has been extensively utilized in the laboratory of Nobel Laureate Randy Schekman and has received high acclaim from his team.

The EXODUS platform has been widely applied across multiple fields, including oncology, neurological diseases, cardiovascular and cerebrovascular diseases, virology and vaccine development, regenerative medicine, and medical aesthetics.

In recent years, research and applications related to exosomes have rapidly gained momentum. As multiple exosome-based therapies globally advance into late-stage clinical trials, the industry is steadily transitioning from "proof of concept" to "industrial realization."

Internationally, the Phase III clinical progress of Capricor Therapeutics and Direct Biologics has become a significant signal for the commercialization of exosome therapies. In China, the inclusion of extracellular vesicles under the ATMP regulatory pathway by the CDE, along with the introduction of Decree No. 818, has established a clear institutional framework for IIT and clinical translation.

Against this backdrop, stable, reproducible, and regulatory-compliant separation and purification capabilities are emerging as critical infrastructure shaping the industry's development.

Table 1: Some IITs Conducted in China Since 2025

As a core enterprise in the upstream industrial chain, Huixin Lifetech's technology platform has gradually expanded to the separation and purification of various types of nanoparticles, such as viruses and LNPs. Guided by a unified engineering approach, Huixin Lifetech bridges the transition from research methods to industrial scale-up, providing a versatile tool platform for nanoparticle drug development and biomanufacturing. In the future, Huixin Lifetech will continue to deepen its expertise in the exosome field while actively expanding into nanoparticles such as viruses and LNPs, consistently delivering efficient separation and purification platforms and solutions for global research and industrial clients, thereby accelerating industry progress.

Huixin Lifetech warmly invites interested investment institutions and business partners to discuss collaboration opportunities and jointly explore future development prospects.